FPMAJ to Present Evidence Showing Revenue from Premium for New Drug Development Is Being Invested in New Drugs

Yoshiaki Kamoya Yoshiaki Kamoya, chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI Drug Pricing Committee, said at a press conference on June 12 that the industry needs to present evidence that the revenue it has received...read more